Sesen Bio to Host Conference Call to Review First Quarter Financial Results & to Provide Operational Update Highlighting Posi...
04 May 2020 - 10:00PM
Business Wire
Sesen Bio (Nasdaq: SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment
of patients with cancer, today announced that Company management
will host a conference call and webcast on Monday, May 11, 2020 at
8:00 a.m. ET to review operating results for the first quarter
ended March 31, 2020. The Company will also provide an update on
the progress of manufacturing activities related to demonstrating
analytical comparability between clinical batches of Vicinium and
validation batches of Vicinium intended for potential future
commercial use.
To participate in the conference call, please dial (844)
831-3025 (domestic) or (315) 625-6887 (international) and refer to
conference ID 3780957. The webcast can be accessed in the Investor
Relations section of the Company's website at www.sesenbio.com. The
replay of the webcast will be available in the investor section of
the Company’s website at www.sesenbio.com for 60 days following the
call.
About Vicinium®
Vicinium, a locally administered fusion protein, is Sesen Bio’s
lead product candidate being developed for the treatment of
high-risk non-muscle invasive bladder cancer (NMIBC). Vicinium is
comprised of a recombinant fusion protein that targets epithelial
cell adhesion molecule (EpCAM) antigens on the surface of tumor
cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
Vicinium is constructed with a stable, genetically engineered
peptide tether to ensure the payload remains attached until it is
internalized by the cancer cell, which is believed to decrease the
risk of toxicity to healthy tissues, thereby improving its safety.
In prior clinical trials conducted by Sesen Bio, EpCAM has been
shown to be overexpressed in NMIBC cells with minimal to no EpCAM
expression observed on normal bladder cells. Sesen Bio is currently
conducting the Phase 3 VISTA trial, designed to support the
registration of Vicinium for the treatment of high-risk NMIBC in
patients who have previously received a minimum of two courses of
bacillus Calmette-Guérin (BCG) and whose disease is now
BCG-unresponsive. Additionally, Sesen Bio believes that cancer
cell-killing properties of Vicinium promote an anti-tumor immune
response that may potentially combine well with immuno-oncology
drugs, such as checkpoint inhibitors. The activity of Vicinium in
BCG-unresponsive NMIBC is also being explored at the US National
Cancer Institute in combination with AstraZeneca’s immune
checkpoint inhibitor durvalumab.
About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical company advancing
targeted fusion protein therapeutics for the treatment of patients
with cancer. The Company’s lead program, Vicinium®, also known as
VB4-845, is currently in a Phase 3 registration trial for the
treatment of high-risk, BCG-unresponsive non-muscle invasive
bladder cancer (NMIBC). In December 2019, the Company initiated the
BLA submission for Vicinium to the FDA under Rolling Review.
Vicinium is a locally administered targeted fusion protein composed
of an anti-EpCAM antibody fragment tethered to a truncated form of
Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. For
more information, please visit the company’s website at
www.sesenbio.com.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, the Company’s strategy, future
operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the safety and
efficacy of Vicinium, the uncertainty inherent in the conduct of
clinical trials, and other factors discussed in the “Risk Factors”
section of the Company’s Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q and other reports filed with the Securities
and Exchange Commission. In addition, the forward-looking
statements included in this press release represent the Company’s
views as of the date hereof. The Company anticipates that
subsequent events and developments will cause the Company’s views
to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200504005019/en/
Erin Clark, Vice President, Corporate Strategy & Investor
Relations ir@sesenbio.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2024 to May 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From May 2023 to May 2024